Liver Chemistries in Patients with COVID‐19 Who Discharged alive or Died: A Meta‐analysis

Xing, Qing‐Qing; Dong, Xuan; Ren, Yan‐Dan; Chen, Wei‐Ming; Zeng, Dan‐Yi; Cai, Yan‐Yan; Hong, Mei‐Zhu; Pan, Jin‐Shui

BACKGROUND & AIMS: Although abnormal liver chemistries are linked to a higher risk of coronavirus disease 2019 (COVID‐19)‐related death, liver manifestations may be diverse and even confusing. Thus, we performed a meta‐analysis of published liver manifestations and described the liver damage in patients with COVID‐19 who died or discharged alive. APPROACH & RESULTS: We searched PubMed, Google Scholar, medRxiv, bioRxiv, the Cochrane Library, Embase, and three Chinese electronic databases through April 22, 2020. We analyzed pooled data on liver chemistries stratified by the main clinical outcome of COVID‐19, using a fixed or random‐effects model. In our meta‐analysis of 19 studies, which included a total of 4,103 patients, the pooled mean alanine aminotransferase and aspartate aminotransferase levels were respectively 31.7 and 51.0 IU/L in the patients with COVID‐19 who died and 27.7 and 32.9 IU/L in those discharged alive (both p < 0.0001). Compared with the patients discharged alive, those who died tended to have lower albumin levels but longer prothrombin time and higher international standardized ratio. CONCLUSIONS: In this meta‐analysis, according to the main clinical outcome of COVID‐19, we comprehensively described three patterns of liver impairment related to COVID‐19, hepatocellular injury, cholestasis, and hepatocellular disfunction. The patients who died from COVID‐19 tended to have different liver chemistries from those discharged alive. Special caution should be given to the patients with relatively higher index of liver chemistries.